HONG KONG DRUG LICENSING

Hong Kong Drug Licence FAQs

Search 500 Hong Kong drug licence FAQs on applications, personnel, premises, quality systems, ongoing regulation, renewals and acquisitions.

Information status: The original FAQ material dates from 2025 and is provided for topic-based reference; it does not represent an individual verification of all 500 FAQs against current rules. For application, fee, renewal, change, product or prescription requirements, please refer to the current official forms and guidance.

Official information from the Drug Office Official information from the Chinese Medicines Board

找到 50 条结果，第 1／3 页。每页显示 20 条；无需启用 JavaScript。

Thematic illustration for pharmaceutical licensing business queries and document organisation services — Discuss actual operating questions one-to-one to clarify the next decision.

Q201 · 在正式提交香港药品批发商牌照申请前，我需要完成哪些核心准备工作？独立链接

Before deciding to start the application process for a Hong Kong Wholesale Dealer Licence, you must make thorough preparations to ensure a smooth application. First, you need to establish a Hong Kong limited company and determine an organisational structure that complies with the Companies Ordinance. Second, and crucially, you must identify and lease commercial premises that meet the strict requirements of the Drug Office, Department of Health (DPO). The premises must satisfy specific physical requirements for the storage, management and distribution of medicines, such as temperature and humidity control, security and adequate space. You must also appoint a qualified Responsible Person (RP) with a relevant pharmaceutical background or experience in the pharmaceutical industry. In addition, it is essential to establish an initial set of Quality Management System (QMS) documents, including Standard Operating Procedures (SOPs). These preparations form the foundation for the subsequent application.

📘 Regulatory basis

Under the Pharmacy and Poisons Ordinance (Cap. 138) and the Pharmacy and Poisons (Wholesale Licences) Regulations, applicants must demonstrate that they have suitable premises, equipment and qualified personnel. The Wholesale Dealers’ Code of Practice published by the PPB sets out detailed requirements for premises, personnel and quality systems.

📗 Drew Tang's recommendations

We strongly recommend that clients ask a consultant from Rengangyongsheng (Hong Kong) Limited to conduct a preliminary assessment of the proposed premises before signing any lease, to avoid an application being rejected because of an unsuitable location. We can also help you shortlist and interview the Person-in-Charge, ensuring that their qualifications meet the PPB's expectations, and draft core SOP documents in advance to prepare thoroughly for the subsequent site inspection.

📕 Risk notice

The greatest risk is non-compliant premises. If structural problems or an inability to meet pharmaceutical storage conditions are discovered only after the application has been submitted, this may not only delay the application but also waste all the rent and fitting-out costs already invested. Due diligence on the premises is therefore the most important risk-control step before applying.

Q202 · 递交香港药牌申请时，如何正确填写申请表格并准备随附文件？独立链接

Submitting an application is the formal start of the entire process, and its accuracy and completeness directly affect the progress of the approval process. Download the latest application form from the Drug Office, Department of Health website (for example, Form B for a Wholesale Dealer Licence). When completing it, ensure that all information, particularly the company name, address, directors and persons in charge, exactly matches your Business Registration Certificate (BR) and Certificate of Incorporation (CI). Even minor discrepancies may lead to a request for further information. The accompanying documents usually include company registration documents, the Business Registration Certificate, a premises layout plan for the proposed medicine warehouse (showing functional areas in detail), CVs and proof of qualifications for the person in charge and their deputy, and copies of identification documents for the company directors. All documents must be certified as required and collated for review by the officers.

📘 Regulatory basis

The Department of Health’s application guide clearly lists the forms and documents to be submitted. Under the Pharmacy and Poisons Regulations, applicants are responsible for providing true, accurate and complete information. Any false statement may result in the application being refused and may even give rise to legal liability.

📗 Drew Tang's recommendations

RGYS may assist with document preparation and project coordination within the written scope of services; the respective responsible parties must verify personnel qualifications and statutory roles and take responsibility for professional judgements, while approval is determined independently by the competent authority. Experience shows that attention to detail determines success or failure. We will provide you with a customised document checklist and review all the materials you prepare item by item to ensure that their format and content are entirely correct. In particular, we will engage a professional drafter to prepare the premises plans, clearly marking the goods receiving area, storage area, returns area, office and other areas, giving reviewing officers a professional and meticulous first impression.

📕 Risk notice

The most common causes of delay are incomplete documents or inconsistent information. For example, the experience described in the responsible person's CV may not be relevant to pharmaceutical wholesale, or the premises layout plan may be too basic to reflect the actual layout. These seemingly minor issues may prompt the Drug Office to issue a request for further information, extending the entire approval process by weeks or even months.

Q203 · 卫生署药剂师督察的现场视察（Site Inspection）主要关注哪些方面？独立链接

An on-site inspection is a key stage in the approval process and usually takes place after an application has been submitted and passed an initial review. A pharmacist inspector will visit your proposed premises to conduct a thorough inspection and verify that you have the operational capability to comply with the law. The inspection will focus mainly on the following: first, checking that the actual layout, facilities and equipment match the submitted plan and meet medicine storage requirements, such as temperature and humidity monitoring, pest control and security systems. The inspector will then assess your Quality Management System, sample-check your Standard Operating Procedure (SOP) documents and may ask the Person-in-Charge about the procedures they contain. Finally, the inspector will interview the Responsible Person (RP) to assess their understanding of the regulations, their awareness of their duties and their ability to handle unexpected incidents. The inspection is intended to ensure that both your physical facilities and management systems can safeguard the quality and safety of medicines during distribution.

📘 Regulatory basis

On-site inspections are based on the Code of Practice for Holder of Wholesale Dealer Licence. The Code sets out specific requirements for premises, storage, personnel, document management, distribution, complaints and recalls, and is the inspection benchmark.

📗 Drew Tang's recommendations

We recommend conducting a comprehensive internal mock audit immediately upon receiving an inspection notice. Rengangyongsheng (Hong Kong) Limited’s consultants will act as inspectors, pre-checking your premises and documents against official standards and providing mock interview training for the Person-in-Charge. This can effectively identify potential issues and allow them to be corrected before the formal inspection, significantly increasing the likelihood of passing first time.

📕 Risk notice

Failure to pass an inspection can have serious consequences. If major deficiencies are identified, such as an ineffective temperature-control system or missing SOP documents, your application will be put on hold until you have completed corrective actions and applied for a re-inspection. This can significantly extend the approval process, and repeated re-inspections may also leave the PPB with a negative impression, making final approval more difficult.

Q204 · 药剂业及毒药管理局（PPB）委员会在审批我的申请时，主要考量哪些因素？独立链接

The Pharmacy and Poisons Board (PPB) is the final approval authority for pharmaceutical licence applications in Hong Kong. After receiving the inspection report and recommendations from Drug Office pharmacist inspectors, the Board will meet to consider your application. Its primary concern is public safety and health. Specifically, the Board will assess several aspects: first, whether the applicant (the company) is a “fit and proper” licence holder, including the company’s background, reputation and any past record of non-compliance. Second, whether the Person-in-Charge (RP) has sufficient knowledge, experience and ability to supervise all activities under the pharmaceutical licence. Third, whether the business premises fully comply with all regulatory requirements and can ensure the safety and quality of medicines. Finally, the Board will review the inspectors’ report, particularly any deficiencies or concerns noted. The licence application will be approved only when the Board is satisfied that the applicant is fully prepared to operate lawfully and compliantly.

📘 Regulatory basis

Section 12 of the Pharmacy and Poisons Ordinance (Cap. 138) confers on the PPB the power to approve, refuse or grant a licence application subject to conditions. The Board’s decision is based on a comprehensive assessment of whether the applicant meets the requirements of the Ordinance and all subsidiary legislation.

📗 Drew Tang's recommendations

It is essential to demonstrate professionalism and a commitment to compliance to the Board. In addition to ensuring a strong performance during the on-site inspection, a clearly structured and detailed application package carefully prepared by Rengangyongsheng for you can strengthen your application. We will highlight your company’s strengths, the person-in-charge’s qualifications and the robustness of your Quality Management System to help the Board reach a positive assessment.

📕 Risk notice

Any factor that may cause the Committee to doubt an applicant’s integrity or competence presents a substantial risk. For example, a company director may have a poor record in another industry, or the applicant may be found to have provided false information during the application process. Even if the physical facilities are perfect, such shortcomings in the “soft” aspects may lead the Committee to exercise its discretion and ultimately reject the application.

Q205 · 如果我的申请被要求补件，应该如何处理？这会对我最终获批产生负面影响吗？独立链接

Receiving a Request for Further Information from the Drug Office, Department of Health is a common occurrence during the application process and is no cause for undue concern. It usually means the reviewing officer has found something unclear, incomplete or inconsistent in your application materials. The appropriate response is to read the notice carefully and fully understand what the officer is asking you to provide or clarify. Then immediately prepare the requested documents or information, ensuring that your submission addresses every question precisely. Finally, submit it in writing, together with all supporting documents, by the specified deadline. A properly handled response will not usually have a direct adverse effect on the final decision, as the reviewing officer treats it as a process for clarifying the facts. It will, however, extend the overall approval timeline.

📘 Regulatory basis

A request for further information is itself part of the regulatory authority’s due diligence and is intended to ensure that all application information complies with the Pharmacy and Poisons Regulations. Applicants are obliged to cooperate with the regulatory authority and provide all information necessary for its review.

📗 Drew Tang's recommendations

When faced with a request for further information, the key is to respond “quickly” and “precisely”. We can help you interpret the official letter promptly and explain what it requires. For example, if evidence of a Responsible Person’s experience is requested, we can recommend more persuasive documents, such as a reference from a former employer or a description of relevant project experience, rather than a simple employment certificate.

📕 Risk notice

Mishandling a request for further information is a major risk. Examples include delaying submission, submitting materials that still do not meet the requirements, or responding in a confrontational manner to the officers. Repeated requests for further information may give reviewing officers the impression that you are ill-prepared or unprofessional. While this will not directly result in rejection, it may make subsequent reviews more stringent and increase uncertainty.

Q206 · 申请香港药牌时，哪些是导致审批流程延误的最常见原因？独立链接

In our years of practice, we have observed several recurring causes of approval delays. The most common is inadequate preparation of application documents, including incorrect information, missing documents and failure to follow the required format. This directly triggers requests for further information and can cost several weeks. Second, the leased premises may have compliance issues, such as inadequate fire safety, a lack of an independent temperature-control system or insufficient security. This can prevent the site inspection from being passed at the first attempt and require substantial time for remediation and reinspection. Third, the appointed Responsible Person (RP) may lack the necessary qualifications or have an unclear understanding of the regulations, and perform poorly in an interview with inspectors, raising concerns about their ability to fulfil the role. External factors, such as a backlog of individual applications at government departments or public holidays, may also affect the overall approval time to some extent. Avoiding these controllable internal causes of delay is key to expediting approval.

📘 Regulatory basis

Almost all delays can be traced to a failure to fully meet the requirements of the Pharmacy and Poisons Ordinance and its subsidiary legislation, as well as the various codes of practice issued by the PPB. The regulatory authorities are responsible for enforcing these requirements rigorously. Any non-compliance will be regarded as a potential risk and may trigger a more cautious review.

📗 Drew Tang's recommendations

“Prevention is better than cure.” The core of Rengangyongsheng (Hong Kong) Limited’s service is proactive risk management at every stage of an application. From selecting premises and matching personnel to preparing documents, we use checklists and pre-submission reviews to ensure the application is in impeccable shape from the outset, fundamentally preventing delays caused by issues within your control.

📕 Risk notice

Do not underestimate the knock-on effects that any “minor issue” may cause. A simple spelling error in an address could mean that all documents have to be redone; a seemingly insignificant omission in an SOP could cause the entire site inspection to fail. These delays can accumulate, extending an approval process originally expected to take a few months to more than a year and greatly increasing your time and opportunity costs.

Q207 · 是否有任何“技巧”可以合法地加速香港药牌的审批流程？独立链接

In a jurisdiction as firmly governed by the rule of law as Hong Kong, there is no “back door” to “jump the queue” or bypass normal procedures. So-called “expediting techniques” are essentially about understanding the approval process in depth and preparing for compliance to the highest standard, thereby reducing all possible causes of delay and achieving approval as quickly as circumstances allow. The most important technique is to “get it right first time”. Engage experienced professional consultants like us to ensure from the outset that your premises, personnel and documents fully meet or even exceed regulatory requirements. Second, maintain professional and smooth communication with the regulatory authorities. Responding promptly, accurately and professionally to their enquiries throughout the application process can build mutual trust. Finally, rehearse thoroughly, particularly for the site inspection and the Responsible Person interview, so that you perform well when it matters. These are not shortcuts, but the only proper route to faster approval.

📘 Regulatory basis

Hong Kong’s legal system emphasises fairness, impartiality and transparency. The Department of Health and PPB apply the same approval processes to all applicants. Their internal working manuals and guidelines strictly specify the assessment criteria and procedures; any attempt to influence their independent judgement is not permitted.

📗 Drew Tang's recommendations

Our value lies not in offering a “fast track”, but in paving a “clear path”. Drawing on our analysis and review of hundreds of cases, we can accurately anticipate the regulator’s areas of focus at each stage and prepare the right responses in advance. This forward-looking professional service is the most effective “accelerator” available to you.

📕 Risk notice

Beware of any promises of “inside connections” or a “guarantee of a licence in no time”. Such promises are almost impossible in Hong Kong’s regulatory environment and may involve fraud. Relying on false promises not only wastes your money, but may also result in your company being blacklisted for involvement in improper conduct, with lasting adverse effects on any future licence applications.

Q208 · 在PPB委员会会议之后，我需要等待多久才能知道最终的审批结果？独立链接

After your application has been submitted for consideration at a Pharmacy and Poisons Board (PPB) meeting, you will not normally be informed of the result immediately. After the meeting, the Drug Office, Department of Health needs time to process the resolutions and prepare formal written notification. Generally, you can expect to receive an official letter within 2 to 4 weeks after the meeting, notifying you of the outcome of your application. The letter will state clearly whether your licence application has been approved, approved subject to conditions, or refused. If approved, it will specify the procedure for collecting the licence and the licence fees payable. If refused, it will explain the reasons. Although this waiting period may be anxiety-provoking, it is part of the standard administrative process.

📘 Regulatory basis

The PPB operates under the Pharmacy and Poisons Ordinance. Notifying applicants in writing through official channels after a decision has been made is part of the statutory procedure and ensures that the notice is formal and authoritative. No statutory provision specifies a timeframe for notification, although government departments generally follow their internal performance pledges.

📗 Drew Tang's recommendations

During this waiting period, we recommend that clients remain patient and begin preparing for operations in the event of approval, for example by finalising supplier contracts and recruiting general staff. We will closely monitor PPB announcements and use our experience to assess the likely outcome of your case. Once we receive a notification, we will explain it to you immediately and guide you through all subsequent steps.

📕 Risk notice

During this period, please avoid calling the Department of Health frequently to ask for the result. Repeated enquiries will not help speed up the process and may instead give officers an unprofessional impression. All formal outcomes should be confirmed by written notice. Information from unofficial channels is unreliable, so do not make business decisions based on rumours.

Q209 · 如果我的申请需要进行负责人（RP）面试，面试通常会涉及哪些内容？独立链接

Although not all applications require a formal interview for the Responsible Person (RP), an interview may be requested in certain circumstances, for example, if the PPB has doubts about the RP’s experience or understanding of the regulations. The main purpose is to assess whether the RP genuinely has the ability and knowledge needed to supervise the licensed business. The interview will generally cover the following areas. First, understanding of Hong Kong pharmaceutical legislation, particularly the Pharmacy and Poisons Ordinance and relevant codes of practice. Second, the RP’s role and responsibilities in the Quality Management System (QMS), such as handling product complaints and initiating and conducting medicine recalls. Third, scenario questions may be used to test the RP’s ability to respond and make decisions in unexpected situations, such as abnormal warehouse temperature or humidity or an accident during transport. The interviewer will want to confirm that the RP is not merely a nominal person in charge but a professional with practical management ability.

📘 Regulatory basis

The Code of Practice for Wholesale Dealers expressly requires a licence holder to appoint a person-in-charge with appropriate authority and resources to discharge their duties and ensure the quality of medicines. An interview is one way for the PPB to verify whether that person is “fit and proper”.

📗 Drew Tang's recommendations

If you receive an interview notice, we will immediately begin an intensive interview coaching programme for your RP. A senior consultant from Rengangyongsheng (Hong Kong) Limited will conduct a one-to-one mock interview, covering all questions that may be asked and refining the RP's answers to ensure they are clear, logical and confident, and demonstrate convincing professional competence to the Committee.

📕 Risk notice

Poor performance by the RP at interview is one of the direct reasons an application may fail. If the RP has only a superficial understanding of key regulations, or makes incorrect judgements in scenario-based questions, the Committee will have good reason to consider them incapable of fulfilling the role and reject the entire licence application. The interview must therefore be taken seriously and prepared for as the most critical stage.

Q210 · 成功获批后，领取牌照的具体流程是怎样的？独立链接

Congratulations! Once you receive the PPB Committee’s formal letter of approval, you will enter the final stage of obtaining your licence. The process is relatively straightforward: first, the approval letter will state the licence fee payable, for example, the issue fee for a wholesaler’s licence is HKD$2,150 (the fee may be revised; refer to the official notice). Pay the fee by the method and within the time limit specified in the letter, and keep the receipt safe. Next, bring the payment receipt, the original approval letter and valid proof of identity for the person collecting the licence (such as a company director or authorised representative) to collect it at the specified time and place, usually the Drug Office, Department of Health. You will need to sign an acknowledgement when collecting the licence. Once you have it, make a copy and keep the original safe, and display the licence prominently at your business premises as required. Your company may then officially begin lawful business activities involving medicines.

📘 Regulatory basis

The Pharmacy and Poisons Regulations provide for the issue of licences and the applicable fees. They also require licence holders to display their licences at the premises. These are basic legal requirements that must be observed after a licence is issued.

📗 Drew Tang's recommendations

Before you collect the licence, we will remind you again of all the documents you need to bring and recommend that you check all the details on the licence on the spot, including the company name, address and licence validity period, to ensure they are correct. We will also provide you with a ‘post-licensing compliance checklist’ to help you operate properly from day one and avoid compliance issues later.

📕 Risk notice

Obtaining a licence does not mean that compliance can be taken for granted. The greatest risk is “lax compliance after opening”. The Department of Health conducts both regular and unannounced inspections. If a subsequent inspection finds that your operations do not meet the standards originally undertaken (for example, SOPs are not followed or records are incomplete), your licence may be suspended or even revoked. Ongoing compliance is therefore the lifeline of a long-term business.

Q211 · 申请中药材零售商牌照和申请西药批发商牌照在流程上有什么主要区别？独立链接

Although both Chinese herbal medicine retail licences and Wholesale Dealer Licences are administered by the Department of Health, they fall under different departments, with significantly different approval processes and areas of focus. First, the regulatory authorities differ: Chinese medicine licences are handled by the Chinese Medicine Regulatory Office (CMRO), while Western medicine licences are handled by the Drug Office (DPO). Second, personnel requirements differ: Chinese medicine retailers must employ a sufficient number of qualified Chinese medicine practitioners according to the shop’s size, such as Chinese herbal medicine dispensers or Chinese medicine dispensers, whereas Western medicine wholesalers must appoint an RP. Third, premises requirements differ: Chinese herbal medicine retail shops need designated areas for displaying, storing and dispensing Chinese herbal medicines, and must comply with the storage guidance in the Hong Kong Chinese Materia Medica Standards; Western medicine wholesale warehouses place greater emphasis on temperature and humidity control, security and logistics management. Finally, the governing legislation differs: the former is mainly governed by the Chinese Medicine Ordinance (Cap. 549), while the latter is governed by the Pharmacy and Poisons Ordinance (Cap. 138).

📘 Regulatory basis

The Chinese Medicine Ordinance (Cap. 549) and its subsidiary legislation provide the main legal framework for licensing Chinese medicine traders. The Pharmacy and Poisons Ordinance (Cap. 138) and its subsidiary legislation provide the legal basis for regulating Western medicine distributors.

📗 Drew Tang's recommendations

We recommend that clients clearly define their business model before deciding which application to pursue. Rengangyongsheng (Hong Kong) Limited has extensive experience handling both types of licence application and can tailor an application strategy to your specific business (retail or wholesale, Chinese medicine or Western medicine), helping you avoid going down the wrong path by confusing the requirements of the two systems.

📕 Risk notice

The greatest risk is “mixing things up” by preparing a Chinese medicine licence application using the approach for a Western medicine licence, or vice versa. For example, equipping a Chinese medicine shop with an expensive, comprehensive air-conditioning system while overlooking the requirement to store products according to the characteristics of Chinese medicines. This mismatch in understanding can result in numerous non-compliances during the on-site inspection and lead to application failure.

Q212 · 如果我的公司计划同时经营药品和医疗器械，申请流程有何不同？独立链接

This is an excellent question and demonstrates forward-thinking about business expansion. In Hong Kong, medicines and medical devices are governed by two separate regulatory systems. Medicines are regulated by the Drug Office, Department of Health and the PPB, and you need to apply for the various pharmaceutical licences discussed above. Medical devices are regulated by the Medical Device Division (MDD) under the Department of Health. Hong Kong currently regulates medical devices through a voluntary listing system known as the Medical Device Administrative Control System (MDACS). Although listing is voluntary, most importers and distributors apply to list their medical devices to demonstrate product safety and efficacy and to supply public organisations such as the Hospital Authority. You therefore need to submit a separate application to the MDD to demonstrate that your company meets the requirements of the Code of Practice for Importers and Distributors under the Medical Device Administrative Control System, including establishing a Quality Management System (such as ISO 13485). The two application processes run in parallel and do not affect each other, but you must satisfy two different sets of regulations and standards.

📘 Regulatory basis

Medicines are regulated under the Pharmacy and Poisons Ordinance. Medical devices are regulated under the guidelines and codes of the Medical Device Administrative Control System (MDACS). Mandatory registration will be introduced when the Medical Devices Ordinance comes into force.

📗 Drew Tang's recommendations

We recommend that you manage the two applications as separate projects. Rengangyongsheng (Hong Kong) Limited can handle medicines licence applications and provide end-to-end consultancy services for medical device listing. We can help you establish an integrated quality management system that meets the GSP (Good Distribution Practice) requirements for medicines and the ISO 13485 standard for medical devices, delivering an efficient “one system, two licences” management model.

📕 Risk notice

The risk lies in confusing the two sets of quality management requirements. For example, it would be wrong to assume that the temperature and humidity recording method used in pharmaceutical warehouses is entirely suitable for all medical devices. Some medical devices have specific requirements for electrostatic control or light exposure. If these are not reflected in the SOPs, they may be identified as serious deficiencies during an MDD audit or later inspection, affecting your business reputation.

Q213 · 从递交申请到最终获批，申请一个西药批发商牌照通常需要多长时间？独立链接

This is a question of great concern to all applicants. According to the service pledge published by the Drug Office, Department of Health, it aims to complete the processing of wholesale dealer licence applications within 5 months of receiving all the required documents and fees. However, this is only an ideal timeframe. In our practical experience, the duration of the entire process depends on several factors. If your application documents are impeccable, the premises pass inspection first time, and the Person-in-Charge performs well, approval within 5 to 6 months is entirely possible. However, if there are any setbacks along the way—for example, further documents are required, the premises need rectification, the Person-in-Charge changes, or a committee interview is needed—the process may take 9 months or even more than 12 months. A more realistic expectation is therefore 6 to 9 months.

📘 Regulatory basis

The “performance pledges” published on the Department of Health website are internal management targets intended to give the public a general indication of timescales. They are not legally guaranteed, and actual processing times vary according to the complexity of each case and the volume of applications.

📗 Drew Tang's recommendations

Time is money. To reduce the approval timeframe as much as possible, we follow a “zero-defect” application principle. Before formal submission, we conduct several rounds of internal review to ensure that everything is in order. We will prepare a detailed project schedule for you, setting out the objectives and milestones for each stage so that you have a clear overview of the entire process. Choose us for the most efficient route to approval.

📕 Risk notice

The greatest time risk is underestimating the complexity of the preparation work and trying to handle the application yourself. Many applicants unfamiliar with the process and standards spend a great deal of time at the initial preparation stage and submit low-quality materials, leading to repeated requests for further information and remedial work. The overall timeframe ultimately far exceeds expectations, substantially affecting the business plan.

Q214 · 我的申请被PPB委员会有条件批准，这是什么意思？我该怎么做？独立链接

Receiving “Conditional Approval” is a relatively positive sign. It means that the PPB has agreed in principle to your application, but requires you to complete specific corrective actions or meet additional conditions before the licence is formally issued. These conditions are usually based on minor deficiencies identified during an on-site inspection, or on an area that the Board considers needs to be strengthened. For example, the Board may require you to “submit detailed staff training records within three months of the licence being issued” or “install a higher-grade security system before formally commencing operations”. You should first carefully review all the conditions listed in the approval letter; then draw up a clear plan to meet each one; and finally, once all conditions have been met, notify the Department of Health in writing and provide supporting documents (such as photographs, receipts and records). The Department of Health will formally issue the licence only after verifying that all conditions have been met.

📘 Regulatory basis

Section 12 of the Pharmacy and Poisons Ordinance expressly authorises the PPB, where it considers appropriate, to attach such conditions to the grant of a licence as it considers appropriate. This is a common tool used by the regulator to manage risks and ensure licence holders’ ongoing compliance.

📗 Drew Tang's recommendations

We will help you interpret the regulatory intent behind each “condition” precisely and provide the most cost-effective and efficient solution. For example, if a condition concerns an SOP revision, we will draft a compliant version for you. We will manage the entire “condition fulfilment” project to ensure that you complete all requirements as quickly as possible and submit a comprehensive response to the Department of Health, so that you can obtain the formal licence as soon as possible.

📕 Risk notice

Taking additional conditions lightly or delaying compliance is a major risk. If you fail to meet all the conditions within the specified period, or the measures you take do not satisfy the Department of Health, the “conditional approval” may be revoked and your application may revert to rejected status. This would mean failing at the final hurdle.

Q215 · 如果我的药牌申请不幸被PPB委员会拒绝，我还有什么后续途径吗？独立链接

If your application is formally rejected by the PPB Committee, this is undoubtedly disappointing, but it is not the end of the world. You have a statutory right of appeal. Under the Pharmacy and Poisons Ordinance, an applicant dissatisfied with a PPB decision may appeal to the Administrative Appeals Board within the specified period after receiving written notification of the rejection (usually 28 days). The Administrative Appeals Board is an independent statutory body that will rehear your case and consider submissions from both you and the PPB. Alternatively, you may choose not to appeal, but instead thoroughly address the reasons given by the PPB in its rejection letter and submit a completely new application at an appropriate time (for example, after 6 months). The choice of route depends on the specific grounds for rejection and your assessment of your circumstances.

📘 Regulatory basis

Section 16 of the Pharmacy and Poisons Ordinance gives applicants the right to appeal to the Appeal Board. This safeguards fairness in administrative proceedings and gives applicants an opportunity for independent review of decisions made by the PPB.

📗 Drew Tang's recommendations

If you receive a refusal letter, we will convene an urgent meeting with you to analyse the underlying reasons for the refusal. If the refusal is based on a misunderstanding of the facts or a debatable interpretation of the law, we will advise and assist you in preparing an appeal, and our legal team will draft a strong statement of appeal. If the refusal is due to significant deficiencies on your part, we will advise you not to appeal, but instead to focus your resources on comprehensive remediation and develop a new, stronger strategy for your next application.

📕 Risk notice

An appeal is a time-consuming and costly process, and success is not guaranteed. Appealing without sound grounds and professional legal support is likely to waste time and money. On the other hand, hastily resubmitting an application without first addressing the issues is almost certain to result in another refusal and may damage your credibility with the regulatory authorities.

Q216 · 在申请过程中，我是否可以与卫生署的审查官员直接沟通，以了解进度或解释我的情况？独立链接

In Hong Kong’s licence application system, communication with the regulatory authorities must follow certain professional protocols. In general, applicants are advised not to contact the officer handling their case frequently or informally to enquire about progress. The Department of Health has its internal procedures and timelines, and repeated calls to chase progress will not help. All formal communications, such as submitting an application or responding to a request for further information, should be in writing to ensure that there is a record of all information. However, in certain circumstances—for example, if you receive a complex request for further information and have a significant query about its requirements—you may, through your professional consultant (such as Rengangyongsheng), formally and professionally ask the Department of Health for clarification. Such communication should address a specific issue, rather than simply enquire about progress.

📘 Regulatory basis

The Hong Kong Government upholds principles of procedural fairness and written records. Although there is no express legal prohibition on verbal communication, formal written documents are relied on for all key administrative decisions and exchanges of information to ensure transparency and avoid disputes.

📗 Drew Tang's recommendations

We will act as a professional bridge between you and regulators. We understand their working language and communication style. When communication is required, we will draft professional correspondence for you or, where necessary, arrange meetings with the relevant departments on your behalf. Having us communicate for you can ensure that your concerns are conveyed clearly and professionally and that the responses you receive are more constructive, avoiding emotional or unprofessional wording that may arise when applicants communicate directly.

📕 Risk notice

Inappropriate direct communication is a major risk. If you challenge an officer’s decision by telephone or attempt to influence their judgement through informal channels, this may be regarded as unprofessional or even improper conduct. This could not only damage your relationship with the regulatory authority but also leave an adverse record in your application file and negatively affect the outcome.

Q217 · 我是否可以在租赁商业办公室的同时，将其一部分用于药品储存以申请牌照？独立链接

This is a common question. Under Hong Kong’s Import and Export Ordinance, if your business consists solely of pharmaceutical product trans-shipment—that is, goods are shipped from one country or region, transhipped in Hong Kong (for example, by changing means of transport in a restricted area at the airport or port), and then continue to another country or region, without leaving the area under Hong Kong Customs control—those goods are not regarded as having been “imported” into Hong Kong. Under this narrowly defined trans-shipment model, you may need to register a company in Hong Kong to conduct business, but you would not generally need to establish your own physical warehouse in Hong Kong that meets GDP standards, because the pharmaceutical products do not enter Hong Kong’s commercial distribution chain. However, you must still ensure that storage and handling during trans-shipment meet GDP requirements in the country of origin, the destination country and during transport.

📘 Regulatory basis

The Code of Practice for Wholesale Dealers is the key reference for premises requirements. It expressly states that “the design and layout of the premises must minimise the risk of cross-contamination and mix-ups” and requires “adequate security measures to prevent unauthorised access”.

📗 Drew Tang's recommendations

We generally recommend that clients choose dedicated industrial buildings or commercial buildings with warehouse areas. If you do wish to adopt a “commercial office plus warehouse” model, we strongly recommend that you ask us to conduct a detailed site survey and feasibility assessment before signing the lease. We will assess the feasibility of physical separation, the building facilities' capacity to support your needs and the associated modification costs, and provide you with a clear, evidence-based recommendation.

📕 Risk notice

The greatest risk is investing heavily in fitting out premises only to be told during an on-site inspection that the physical segregation is non-compliant or prohibited by the building's deed of mutual covenant. For example, glass partitions or half-height wire-mesh fencing alone may well be considered inadequate segregation. In this situation, your entire investment would be wasted and the application could be deadlocked.

Q218 · 申请牌照时，对公司的注册资本有最低要求吗？独立链接

Neither Hong Kong company law nor pharmaceutical regulations set a specific minimum share capital for a company applying for a drug licence. The Hong Kong Companies Registry permits a company to be incorporated with very low share capital (for example, HKD 1). From a legal perspective, the amount of the company’s share capital will not directly determine whether the PPB Committee approves or refuses the application. However, in commercial practice and from the perspective of regulatory scrutiny, a company with a reasonable and robust capital structure is more likely to demonstrate its commitment to long-term operations and ability to withstand risks. Very low share capital may raise some concerns for reviewing officers when they assess whether the company is a fit and proper licence holder. Therefore, although there is no statutory minimum, it is prudent to set share capital at a reasonable level commensurate with the scale of your business.

📘 Regulatory basis

Neither the Companies Ordinance (Cap. 622) nor the Pharmacy and Poisons Ordinance (Cap. 138) prescribes minimum registered capital for a company applying for a drug licence. The PPB focuses on whether the applicant is “fit and proper”, which is assessed on a range of factors.

📗 Drew Tang's recommendations

We recommend that clients set a reasonable registered capital amount, such as HK$100,000 to HK$1,000,000, based on the initial investment and early operating funding requirements in their business plan. This not only signals capability to regulators, but also reflects your serious commitment to the business. We will present the company’s financial soundness as a strength in your application materials.

📕 Risk notice

Although low registered capital will not directly result in refusal, extremely low registered capital for your company, such as just 1 HKD, combined with a lack of other evidence of financial soundness, such as a bank reference or a financial support undertaking from shareholders, may count against you. In an application that is already borderline in other respects, this “last straw” may sometimes influence the Board’s final decision.

Q219 · 我是否需要为我的药品仓库购买特定的保险？这在申请时需要提交证明吗？独立链接

At the licence application stage for various pharmaceutical licences in Hong Kong, neither the Department of Health nor the PPB requires you to provide proof that you have purchased specific insurance. In other words, insurance is not a required document for submitting an application. However, from the perspective of prudent business management and risk control, it is essential to obtain adequate insurance for your medicine warehouse and business, and this is something the regulatory authorities are likely to welcome. Recommended types of insurance include: property all-risks insurance (covering losses to your medicine inventory caused by incidents such as fire or theft); public liability insurance (covering the risk of personal injury or property damage caused to third parties by your business activities); and product liability insurance (covering the risk of harm to users caused by defects in the medicines you sell). Although you do not need to submit proof with your application, being able to show during an on-site inspection that you have planned for or purchased relevant insurance would be a positive point if the inspector asks about your risk management measures.

📘 Regulatory basis

The Code of Practice for Wholesale Dealers requires licence holders to have appropriate arrangements for managing risks, but does not expressly prescribe what commercial insurance must be purchased. This is a business decision, but a responsible operator should have such arrangements in place.

📗 Drew Tang's recommendations

We strongly recommend that all clients have a comprehensive insurance plan in place before commencing operations. Rengangyongsheng (Hong Kong) Limited can connect you with experienced insurance brokers, who can tailor a cost-effective insurance package to your business scale and product types. We can include a section on “Insurance and Risk Management” in your application SOP documents to demonstrate to the regulatory authorities that you have considered these matters carefully and professionally.

📕 Risk notice

The greatest risk is operating “without a safety net”. If an accident occurs, such as a warehouse fire destroying pharmaceutical inventory worth millions, or a medicine-related issue leads to substantial claims, the financial consequences of having no insurance will be catastrophic and may directly result in the company's bankruptcy. Do not expose the entire business to substantial risk just to save on premiums in the short term.

Q220 · 在牌照申请期间，如果我的公司发生了董事或股东变更，我需要通知卫生署吗？独立链接

Yes, this is absolutely required. Throughout the licence application process, you have an ongoing responsibility to ensure that all information submitted to the Department of Health is up to date and accurate. The company's director and shareholder structure is an important factor in the regulatory authority's assessment of whether the applicant is “fit and proper”. Therefore, as soon as there is any appointment or resignation of a director, or a significant change in the shareholding structure (for example, a change of controlling shareholder), you must proactively notify the Drug Office, Department of Health, in writing. You will need to submit the relevant company resolutions, the latest forms filed with the Companies Registry (such as ND2A and NSC1), and identity documents and CVs of newly appointed directors. The regulatory authority needs to carry out the same background checks on new directors or shareholders.

📘 Regulatory basis

Although no law expressly prescribes change notifications “during the application period”, this follows naturally from the fundamental legal obligation to provide true, accurate and complete information. After a licence is issued, the Wholesaler’s Code of Practice expressly requires the licence holder to notify the Department of Health of changes to key personnel and company structure.

📗 Drew Tang's recommendations

We recommend that clients keep their company structure as stable as possible during the application period. If a change is necessary, please notify us immediately. We will guide you in preparing the notification documents and communicate with the Department of Health as professionally as possible, explaining the background and reasons for the change to minimise any potential disruption to the application timetable. We will ensure that the entire process is transparent and compliant.

📕 Risk notice

Failure to disclose is the greatest risk. If the Department of Health discovers through other channels, such as public information from the Companies Registry, that your company structure has changed and you have not notified it, this will be regarded as a serious lack of integrity. The regulator may question your reliability, leading at best to stringent scrutiny and significant delays, and at worst to your application being refused outright. Do not take any chances.

Hong Kong Drug Licence FAQs

Plan Your Hong Kong Pharmaceutical Licensing Project with Drew Tang